Are you looking for information about Lecanemab in Spain or new treatments for Alzheimer’s disease?
Our team can assess your case and provide information about the treatment options available at barnaclínic+.
What is Lecanemab?
Lecanemab, marketed as Leqembi®, is a monoclonal antibody developed for the treatment of certain patients with early-stage Alzheimer’s disease.
The medication targets beta-amyloid protein and promotes the clearance of its deposits from the brain. Unlike treatments primarily aimed at managing the symptoms of Alzheimer’s disease, Lecanemab is designed to target one of the biological processes associated with the disease and slow its progression.
In Europe, Lecanemab is indicated for adult patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease who have confirmed amyloid pathology and who are either non-carriers or heterozygous for ApoE ε4.
Therefore, not all patients with Alzheimer’s disease are eligible for treatment with Lecanemab. Its use requires a specialist assessment to confirm the diagnosis, determine the stage of the disease, and evaluate the necessary clinical, biological, genetic and safety criteria.
What does Lecanemab do? How does this Alzheimer's treatment work?
Lecanemab is a monoclonal antibody that binds to certain forms of beta-amyloid, a protein that accumulates abnormally in the brains of people with Alzheimer’s disease.
This binding facilitates the clearance of beta-amyloid and reduces its accumulation in the brain. The aim of the treatment is not to cure Alzheimer’s disease or restore cognitive abilities that have already been lost, but to slow cognitive and functional decline in selected patients who are in the early stages of the disease.
Clinical trials of Lecanemab showed an approximately 27% reduction in the progression of cognitive and functional decline at 18 months compared with placebo.
How is Lecanemab treatment administered?
Leqembi® is administered by intravenous infusion every two weeks and requires specialist medical supervision.
Before starting treatment, the presence of beta-amyloid pathology must be confirmed and the patient’s ApoE genotype must be determined. A baseline brain MRI is also required, together with follow-up MRI scans during treatment.
One of the main adverse effects requiring monitoring is amyloid-related imaging abnormalities (ARIA), which may include cerebral oedema and small brain haemorrhages. For this reason, appropriate patient selection and neuroimaging monitoring are essential components of treatment.
Is Lecanemab available in Spain?
Lecanemab (Leqembi®) has been authorised in the European Union since 2025, meaning that it has European authorisation for use in Spain within the approved indications.
However, the authorisation of a medicine does not mean that it is available at every centre or that all patients with Alzheimer’s disease are eligible to receive it.
Currently, barnaclínic+ does not offer treatment with Lecanemab.
The Memory and Cognitive Disorders Unit at barnaclínic+ does offer a specialist Alzheimer’s disease assessment, which can confirm the diagnosis, assess the presence of amyloid pathology and determine whether the patient may be eligible for any of the new beta-amyloid-targeting therapies available at our centre.
Lecanemab y Donanemab: nuevos tratamientos para el Alzheimer
Lecanemab is not the only beta-amyloid-targeting treatment developed to modify the progression of Alzheimer’s disease. Donanemab (Kisunla®) also belongs to this new generation of treatments and is authorised in Europe for certain patients with early-stage Alzheimer’s disease.
Although both are monoclonal antibodies that target beta-amyloid, Lecanemab and Donanemab are not the same medication and differ in their specific mechanism of action, dosing schedule, duration of treatment and monitoring protocols.
barnaclínic+ offers Donanemab (Kisunla®) to patients who meet the established criteria for receiving this treatment.
Preguntas frecuentes sobre Lecanemab
Is Lecanemab approved in Spain?
Yes, Lecanemab is available in Spain. It has had a valid marketing authorisation in the European Union since April 2025. Its indication is restricted to certain patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease, with confirmed amyloid pathology and no copies or only one copy of ApoE ε4.
Can I receive Lecanemab treatment at barnaclínic+?
No. Currently, barnaclínic+ does not offer treatment with Lecanemab (Leqembi®).
However, we can provide a specialist assessment for patients with Alzheimer’s disease and determine whether they meet the criteria for other new beta-amyloid-targeting treatments available at our centre, such as Donanemab (Kisunla®).
What is the price of Lecanemab in Spain?
The cost of treatment with Lecanemab may depend not only on the medication itself, but also on the healthcare process required for its indication, administration and follow-up.
barnaclínic+ does not currently offer Lecanemab and therefore does not have a price or Treatment Plan for this treatment.
If you are looking for information about new treatments for Alzheimer’s disease available at barnaclínic+, our team can assess your case and provide information about the available options.
Does Lecanemab cure Alzheimer’s disease?
No. Lecanemab does not cure Alzheimer’s disease or restore cognitive abilities that have already been lost. Its aim is to slow the progression of cognitive and functional decline in certain patients diagnosed in the early stages of the disease.
Are Lecanemab and Leqembi® the same?
Yes. Lecanemab is the active substance and Leqembi® is its brand name.
Are Lecanemab and Donanemab the same?
No. Both are monoclonal antibodies that target beta-amyloid and are indicated for certain patients with early-stage Alzheimer’s disease, but they are different medications.
Donanemab is marketed as Kisunla® and differs from Lecanemab in its specific mechanism of action, dosing schedule and duration of treatment.
Currently, barnaclínic+ offers Donanemab, but not Lecanemab.
What tests are required to assess eligibility for these new Alzheimer’s treatments?
The assessment may include a clinical and neuropsychological evaluation, tests to confirm the presence of beta-amyloid pathology, ApoE genotyping and a brain MRI, as well as any other tests considered necessary by the specialist.
The aim is to confirm that the patient has Alzheimer’s disease at a stage that may be suitable for treatment and to assess the potential benefits and risks on an individual basis.
Are you looking for Alzheimer’s treatment in Barcelona?
Our team can assess the diagnosis, stage of the disease and the necessary biomarkers to determine which treatment options may be appropriate.
Memory and Cognitive Disorders Blog
Frontotemporal dementia: symptoms, diagnosis, and available treatments
Frontotemporal dementia (FTD) is a type of neurodegenerative dementia less common than Alzheimer’s disease, but with a great impact on the patient’s life and their environment. Unlike other dementias, it usually begins at an earlier age, between 45 and 65 years, and its main symptom is not related to memory, but to behavior. What is […] La entrada Frontotemporal dementia: symptoms, diagnosis, and available treatments se publicó primero en Blog de Memoria y Trastornos Cognitivos de barnaclínic+.
Cognitive decline: key facts for early detection and treatment
Cognitive decline is a process involving the loss of mental functions such as memory, language or planning ability. It mostly affects older adults, although it can occur at any age. Recognising the early signs and understanding the different stages of cognitive decline is essential to prevent its progression to more severe forms. “We aim to […] La entrada Cognitive decline: key facts for early detection and treatment se publicó primero en Blog de Memoria y Trastornos Cognitivos de barnaclínic+.